Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

References for PMC Articles for PubMed (Select 21440001)


Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry.

Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Maréchaux S, Eicher JC, Blanchard-Lemoine B, Rousseau J, Hénon P, Jobic Y, Etienne Y.

Eur J Echocardiogr. 2011 Apr;12(4):265-71. doi: 10.1093/ejechocard/jeq172. Epub 2010 Dec 30.


Benfluorex: the last chapter of drug-induced valvular heart disease?

Droogmans S, Cosyns B, Van Camp G.

Eur J Echocardiogr. 2011 Apr;12(4):263-4. doi: 10.1093/ejechocard/jeq181. Epub 2010 Dec 30. No abstract available.


Serotonin receptors - from molecular biology to clinical applications.

Pytliak M, Vargová V, Mechírová V, Felšöci M.

Physiol Res. 2011;60(1):15-25. Epub 2010 Oct 15. Review.


Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.

Weill A, Païta M, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H.

Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1256-62. doi: 10.1002/pds.2044. Epub 2010 Oct 13.


Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects.

Banas SM, Doly S, Boutourlinsky K, Diaz SL, Belmer A, Callebert J, Collet C, Launay JM, Maroteaux L.

Neuropsychopharmacology. 2011 Jan;36(2):423-33. doi: 10.1038/npp.2010.173. Epub 2010 Oct 6.


Strategies to discover unexpected targets for drugs active at G protein-coupled receptors.

Allen JA, Roth BL.

Annu Rev Pharmacol Toxicol. 2011;51:117-44. doi: 10.1146/annurev-pharmtox-010510-100553. Review.


Drug-induced valvulopathy: an update.

Elangbam CS.

Toxicol Pathol. 2010 Oct;38(6):837-48. doi: 10.1177/0192623310378027. Epub 2010 Aug 17. Review.


HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.

Kozikowski AP, Cho SJ, Jensen NH, Allen JA, Svennebring AM, Roth BL.

ChemMedChem. 2010 Aug 2;5(8):1221-5. doi: 10.1002/cmdc.201000186. No abstract available.


Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner.

Balachandran K, Sucosky P, Jo H, Yoganathan AP.

Am J Pathol. 2010 Jul;177(1):49-57. doi: 10.2353/ajpath.2010.090631. Epub 2010 May 20.


PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.

Porvasnik SL, Germain S, Embury J, Gannon KS, Jacques V, Murray J, Byrne BJ, Shacham S, Al-Mousily F.

J Pharmacol Exp Ther. 2010 Aug;334(2):364-72. doi: 10.1124/jpet.109.165001. Epub 2010 Apr 29.


Inflammatory aneurysm of the abdominal aorta in a patient treated with ropinirole.

Parissis D, Papachristodoulou A, Dimitriadis A.

J Neurol. 2010 Sep;257(9):1582-4. doi: 10.1007/s00415-010-5568-6. Epub 2010 Apr 21. No abstract available.


Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Circulation. 2010 Feb 23;121(7):e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667. Epub 2009 Dec 17. No abstract available. Erratum in: Circulation. 2010 Mar 30;121(12):e260. Stafford, Randall [corrected to Roger, Véronique L]. Circulation. 2011 Oct 18;124(16):e425.


Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice.

Doly S, Bertran-Gonzalez J, Callebert J, Bruneau A, Banas SM, Belmer A, Boutourlinsky K, Hervé D, Launay JM, Maroteaux L.

PLoS One. 2009 Nov 23;4(11):e7952. doi: 10.1371/journal.pone.0007952.


Drug-induced fibrotic valvular heart disease.

Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J.

Lancet. 2009 Aug 15;374(9689):577-85. doi: 10.1016/S0140-6736(09)60252-X. Review.


Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression.

Benton JA, Kern HB, Leinwand LA, Mariner PD, Anseth KS.

Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1950-7. doi: 10.1161/ATVBAHA.109.195271. Epub 2009 Aug 13. Erratum in: Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):e322.


The expanded biology of serotonin.

Berger M, Gray JA, Roth BL.

Annu Rev Med. 2009;60:355-66. doi: 10.1146/ Review.


Dose dependency and reversibility of serotonin-induced valvular heart disease in rats.

Droogmans S, Roosens B, Cosyns B, Degaillier C, Hernot S, Weytjens C, Garbar C, Caveliers V, Pipeleers-Marichal M, Franken PR, Bossuyt A, Schoors D, Lahoutte T, Van Camp G.

Cardiovasc Toxicol. 2009 Sep;9(3):134-41. doi: 10.1007/s12012-009-9046-2. Epub 2009 Jul 16.


Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.

Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL.

Mol Pharmacol. 2009 Oct;76(4):710-22. doi: 10.1124/mol.109.058057. Epub 2009 Jul 1.


Fibrosis and carcinoid syndrome: from causation to future therapy.

Druce M, Rockall A, Grossman AB.

Nat Rev Endocrinol. 2009 May;5(5):276-83. doi: 10.1038/nrendo.2009.51. Review.


Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.

Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL.

Psychopharmacology (Berl). 2009 Jul;205(1):119-28. doi: 10.1007/s00213-009-1521-8. Epub 2009 Apr 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk